Vestibular Schwannoma Clinical Trial
Official title:
Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas
Patients undergoing surgery of a vestibular schwannoma will be included in the study. Patients will receive triamcinolone acetonide 24h before surgery. During translabyrinthine surgery cochlear perilymph, perilymph from the semicircular canal and cerebrospinal fluid will be taken and analyzed for triamcinolone content. In patients undergoing middle fossa or retrosigmoid resection only cerebrospinal fluid will be taken and analyzed for triamcinolone acetonide level.
Patients between 18 and 90 years undergoing surgery of a vestibular schwannoma will be included in the study. Patients will be offered an application of triamcinolone acetonide intratympanically on the day before surgery. During surgery samples will be taken to define how much triamcinolone acetonide enters into the perilymphatic fluid, the perilymph of the semicircular canals and CSF. Patients undergoing translabyrinthine surgery will undergoing labyrinthectomy during which samples of the semicircular canal can be taken. During translabyrinthine surgery nerve monitoring will be carried out using an intracochlear electrode. Before inserting the electrode perilymph of the cochlea can be taken. Immediately after opening the dura cerebrospinal fluid will be taken. Patients undergoing middle fossa or retrosigmoid resection of the vestibular schwannoma will not undergo sampling of the perilymph. In these patients cerebrospinal fluid will be taken to determine triamcinolone acetonide levels. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
| Active, not recruiting |
NCT00973739 -
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Completed |
NCT04351373 -
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
|
Phase 2 | |
| Active, not recruiting |
NCT01449604 -
Stereotactic Radiation in Vestibular Schwannoma
|
Phase 3 | |
| Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
| Not yet recruiting |
NCT05567341 -
Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery
|
N/A | |
| Completed |
NCT02249572 -
Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.
|
N/A | |
| Terminated |
NCT05116878 -
Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma
|
N/A | |
| Active, not recruiting |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
| Recruiting |
NCT04801953 -
Nimodipine in Vestibular Schwanommas
|
Phase 2 | |
| Recruiting |
NCT03745560 -
Intraoperative EABR for Decision Making
|
||
| Recruiting |
NCT04859335 -
Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma
|
N/A | |
| Recruiting |
NCT04128345 -
Novel Multimodality Imaging for Navigation in Skull Base Surgery
|
||
| Active, not recruiting |
NCT01199978 -
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
|
Phase 2 | |
| Recruiting |
NCT04057976 -
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
|
N/A | |
| Completed |
NCT00863122 -
Concentration and Activity of Lapatinib in Vestibular Schwannomas
|
Early Phase 1 | |
| Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
| Recruiting |
NCT03079999 -
Study of Aspirin in Patients With Vestibular Schwannoma
|
Phase 2 | |
| Recruiting |
NCT05786144 -
Vestibular Schwannoma Organoids
|
||
| Recruiting |
NCT03593577 -
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
|